Glasdegib Plus Intensive/Nonintensive Chemotherapy in Untreated Acute Myeloid Leukemia: BRIGHT AML 1019 Phase III Trials

Future Oncology - United Kingdom
doi 10.2217/fon-2019-0373
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Secondary Acute Myeloid Leukemia (sAML) Immediately After Intensive Chemotherapy of Acute Lymphoblastic Leukemia (ALL)

Journal of Leukemia
2013English

Immunologic Consequences of Chemotherapy for Acute Myeloid Leukemia

Journal of Pediatric Hematology/Oncology
Child HealthOncologyPediatricsHematologyPerinatology
2013English

Cost-Effectiveness Analysis of Midostaurin (MIDO) With Standard Chemotherapy (SOC) for Acute Myeloid Leukemia (AML) in the United Kingdom (UK)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Acute Myeloid Leukemia

JAMA - Journal of the American Medical Association
Medicine
2010English

Acute Myeloid Leukemia

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention

Frontiers in Pediatrics
Child HealthPediatricsPerinatology
2019English

The Clinical Relevance of Cellular Drug Resistance Testing in Childhood Acute Myeloid Leukemia (AML)

Pediatric Research
Child HealthPediatricsPerinatology
1999English

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Clinical Hematology International
2019English

Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 With Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Biology of Blood and Marrow Transplantation
TransplantationHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy